Cargando…
Improving the Safety of Medicines in the European Union: From Signals to Action
Pharmacovigilance and risk minimization must be planned during drug development and forms a critical part of the regulator's decision on whether a medicinal product can be authorized. Pharmacovigilance systems should ensure proactive monitoring of all authorized medicines throughout their lifec...
Autores principales: | Potts, Joanne, Genov, Georgy, Segec, Andrej, Raine, June, Straus, Sabine, Arlett, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027976/ https://www.ncbi.nlm.nih.gov/pubmed/31621897 http://dx.doi.org/10.1002/cpt.1678 |
Ejemplares similares
-
Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works
por: Santoro, Aniello, et al.
Publicado: (2017) -
What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?
por: Januskiene, Justina, et al.
Publicado: (2020) -
Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human Use
por: Santoro, Aniello, et al.
Publicado: (2020) -
Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs
por: Mazzaglia, Giampiero, et al.
Publicado: (2017) -
Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data
por: Segec, Andrej, et al.
Publicado: (2020)